Predicting and Promoting Human Bone Marrow MSC Chondrogenesis by Way of TGFβ Receptor Profiles: Toward Personalized Medicine.
TGF receptor
chondrogenic differentiation
mesenchymal stem cell
personalized medicine
receptor ratio
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
01
2020
accepted:
20
05
2020
entrez:
18
7
2020
pubmed:
18
7
2020
medline:
18
7
2020
Statut:
epublish
Résumé
The use of human mesenchymal stromal cells (hMSCs) for cartilage regeneration has been hampered by the inherent donor variation of primary monolayer expanded cells. Although CD markers are typically used to characterize cell populations, there is no correlation between CD marker profile and functional outcomes. Therefore, we aimed to discover novel predictive MSC chondrogenesis markers. The chondrogenic potential of primary human bone marrow MSCs (hBMSCs) over multiple passages was assessed by standard pellet culture. We confirmed that the ratio of TGFβ-RI/TGFβ-RII at the time of cell recovery from the tissue culture plastic reliably predicted chondrogenic potential. Furthermore, it is possible to prospectively characterize any human BMSC cell population as responders or non-responders with respect to chondrogenic differentiation potential. Transient increase of the ratio with siRNA knockdown of TGFβ-RII reproducibly recovered the chondrogenic differentiation ability of non-responsive MSCs. Together this offers an opportunity to produce a more functionally characterized cell population for use in autologous cartilage repair therapies.
Identifiants
pubmed: 32676497
doi: 10.3389/fbioe.2020.00618
pmc: PMC7333220
doi:
Types de publication
Journal Article
Langues
eng
Pagination
618Informations de copyright
Copyright © 2020 Rothweiler, Basoli, Duttenhoefer, Kubosch, Schmelzeisen, Johnstone, Alini and Stoddart.
Références
J Immunol. 2009 Jun 15;182(12):7937-45
pubmed: 19494318
J Bone Miner Res. 1996 Sep;11(9):1264-73
pubmed: 8864901
Haematologica. 2009 Feb;94(2):173-84
pubmed: 19066333
Cell. 2003 Jun 13;113(6):685-700
pubmed: 12809600
Arthritis Res Ther. 2005;7(6):R1338-47
pubmed: 16277687
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Stem Cells Int. 2018 Aug 8;2018:4180857
pubmed: 30158983
EMBO J. 1997 Sep 1;16(17):5353-62
pubmed: 9311995
Tissue Eng. 2006 Aug;12(8):2141-9
pubmed: 16968155
Cell Tissue Res. 2014 Jan;355(1):163-71
pubmed: 24192939
Tissue Eng Part A. 2009 Jan;15(1):33-44
pubmed: 18637760
Eur Cell Mater. 2012 Nov 09;24:i-ii
pubmed: 23143921
Aging Cell. 2004 Dec;3(6):379-89
pubmed: 15569355
Stem Cell Reports. 2016 Jun 14;6(6):897-913
pubmed: 27304917
Osteoarthritis Cartilage. 2016 May;24(5):868-72
pubmed: 26687821
Stem Cells Dev. 2017 May 15;26(10):751-761
pubmed: 28300491
J Mol Cell Cardiol. 2014 May;70:56-63
pubmed: 24184998
J Bone Joint Surg Am. 1998 Dec;80(12):1745-57
pubmed: 9875932
Cytokine Growth Factor Rev. 2002 Jun;13(3):241-57
pubmed: 12486877
J Bone Joint Surg Am. 1994 Apr;76(4):579-92
pubmed: 8150826
PLoS One. 2015 Dec 31;10(12):e0146124
pubmed: 26720610
Nat Rev Mol Cell Biol. 2012 Oct;13(10):616-30
pubmed: 22992590
EBioMedicine. 2015 Dec 24;4:62-73
pubmed: 26981553
Cell Tissue Res. 2003 Sep;313(3):281-90
pubmed: 12883998
Tissue Eng Part A. 2015 Jan;21(1-2):115-23
pubmed: 24980654
Tissue Eng Part A. 2011 Apr;17(7-8):1157-67
pubmed: 21142619
J Biol Chem. 1999 Feb 5;274(6):3672-7
pubmed: 9920917
Eur Cell Mater. 2017 Oct 27;34:217-231
pubmed: 29076514
J Mol Med (Berl). 2006 Nov;84(11):901-10
pubmed: 16972087
Stem Cells Dev. 2007 Dec;16(6):965-78
pubmed: 18047418
Stem Cells. 2017 Nov;35(11):2280-2291
pubmed: 28833807
Sci Rep. 2016 Nov 16;6:36655
pubmed: 27848974